Evening Primrose Oil
Best-in-class: Evening Primrose Oil
A source of GLA (gamma-linolenic acid), an anti-inflammatory omega-6 used for skin (eczema), hormonal/PMS and breast-pain support.
Evening Primrose Oil quick facts
| Suggested dose | 500–1,300 mg (standardized GLA) daily. |
| How often | Daily |
| Who it's for | Skin (eczema), PMS and cyclical breast-pain support (women). |
The best-supported use is cyclical mastalgia, where the prolactin-sensitivity mechanism fits the clinical picture. Evidence in eczema is weaker than its popularity implies and several good trials were negative. Lower GLA content than borage means larger doses. It may lower seizure threshold, which matters with phenothiazines and in epilepsy.
How Evening Primrose Oil actually works
The same GLA mechanism as borage at a lower concentration, converting to DGLA and then prostaglandin E1. PGE1 modulates tissue sensitivity to prolactin, which is the specific proposed mechanism for its effect on cyclical breast pain rather than a general anti-inflammatory account.
Where to get Evening Primrose Oil
Find Evening Primrose Oil on iHerb →The evidence for Evening Primrose Oil
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs are mixed but supportive for eczema, cyclical breast pain and some PMS symptoms.
- GLA converts to anti-inflammatory prostaglandins.
📊 Correlative data
- Traditional use by Indigenous North American peoples, and prescribed in the UK for eczema and mastalgia until the license was withdrawn in 2002 because the accumulated evidence did not support efficacy. That withdrawal is one of the more honest data points in the botanical literature.
🧪 Theoretical / extrapolated benefits
- Best for skin and women's hormonal/cyclical complaints.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Evening Primrose Oil actually does
Evening primrose seed oil is about 70% linoleic acid and 8 to 10% gamma-linolenic acid, and it became a prescription medicine in Britain on the strength of one specific, falsifiable idea. That idea is worth stating properly, because it was a good hypothesis and the trials that followed are what happens when a good hypothesis meets its endpoint.
The hypothesis: a blocked enzyme, not a missing nutrient. The proposal was that people with atopic eczema and women with cyclical breast pain have reduced delta-6-desaturase activity — the FADS2-encoded step that converts dietary linoleic acid to gamma-linolenic acid. If that step is slow, then linoleic acid piles up while the downstream products fall, and no amount of ordinary vegetable oil fixes it. Supplying GLA directly steps over the block. That is a mechanism with a prediction attached: the fatty acid profile of affected people should be abnormal in a particular direction, and correcting it should treat the disease.
The modern version of that idea has a genetic substrate, which is why it refuses to die. Common polymorphisms in the FADS1 and FADS2 gene cluster are among the strongest known genetic determinants of circulating GLA, dihomo-gamma-linolenic acid and arachidonic acid concentrations — large effects, in the general population. So the desaturase-capacity hypothesis was not fanciful; it identified a real source of between-person variation. What nobody has ever done is run a GLA trial in people selected by that genotype.
The breast mechanism is about receptor sensitivity, not hormone levels, and that distinction decides what you can measure. Women with cyclical mastalgia typically have normal circulating estradiol and prolactin. The proposal was never that this oil lowers a hormone; it was that altered membrane fatty acid composition changes how responsive breast tissue is to a normal hormonal signal, with prostaglandin E1 and cyclic AMP modulating receptor affinity. Which means a blood test of your hormones is not a test of this product, and a normal result is not reassurance that it should have worked.
One more piece of pharmacology explains the pregnancy advice. Prostaglandin E1 ripens the cervix — that is the mechanism of misoprostol, a licensed PGE1 analog — and it is why this oil has a folk and midwifery use near term and a caution everywhere before it. The mechanism is the same molecule family in both cases; only the timing changes whether it is wanted.
Cell, rodent, human — and where it stops
Cyclical mastalgia, tested properly, with the control arm that makes it informative. One hundred and twenty women were randomized into four groups — fish oil plus a control oil, evening primrose oil plus a control oil, both active oils, or both control oils — for six months. Days with pain fell by 12.3% on evening primrose oil and by 13.8% on its control oil (P = .73), and by 15.5% on fish oil against 10.6% on its control (P = .28). The authors concluded that neither oil offered clear benefit over the control oils Blommers 2002. Read the control numbers again: an inert oil produced a 13.8% reduction in painful days. That is the size of the effect this product has to beat, and it did not.
Eczema, pooled, and the interval tells the story. A Cochrane review of 27 studies and 1,596 participants found evening primrose oil failed to significantly improve eczema, mean difference −2.22, 95% CI −10.48 to 6.04 Bamford 2013. A confidence interval straddling zero across 27 trials is not an under-powered literature awaiting a better study; it is an answer.
The regulatory history is the honest headline of this product. Evening primrose oil held UK marketing authorizations as a prescription treatment for atopic eczema and mastalgia, and those authorizations were withdrawn in 2002 because the accumulated evidence did not support efficacy. The Cochrane review is the quantitative version of that decision Bamford 2013. Very few supplements have ever been examined at that standard, and fewer still failed in public.
Now the arithmetic, because it is the reason none of this is quite the end. Evening primrose oil is roughly 9% GLA, so a 1,000 mg capsule delivers about 90 mg of gamma-linolenic acid. The dose range on this card — 500 to 1,300 mg — is therefore about 45 to 117 mg of GLA a day. The only clean positive result for GLA in an inflammatory disease used 2.8 grams a day Zurier 1996: about thirty-one 1,000 mg evening primrose capsules. Consumer dosing is somewhere between one twenty-fourth and one sixtieth of that.
So the obstacle is stated fairly like this. What failed in the eczema and mastalgia trials was evening primrose oil at doses people actually take Blommers 2002 Bamford 2013. What has never been tested in those indications is GLA at the dose that worked somewhere else Zurier 1996. Both sentences are true, and the second one is not a rescue — it is a description of an experiment nobody has funded in thirty years, which is itself evidence about how much anyone expects from it.
Evening Primrose Oil — which form, and does it matter
Buy the GLA number, because the oil number is misleading by design. Evening primrose is 8 to 10% GLA against borage's 20 to 25%, so a 1,000 mg capsule of each differs roughly threefold in the active molecule. A label that states GLA in milligrams lets you compare with the trials Zurier 1996 Blommers 2002; a label that states only oil mass makes you do arithmetic on an assumed percentage.
The one place evening primrose beats borage outright. Oenothera biennis does not make pyrrolizidine alkaloids, so the hepatotoxicity question that dominates borage's safety section does not arise here at all. If you want GLA and you want to stop thinking about alkaloid certification, this is the source that lets you — at the cost of two to three times as many capsules for the same GLA.
Cold-pressed and tocopherol-protected, in dark packaging. GLA has three double bonds; the oil oxidizes and a rancid capsule delivers peroxides instead of fatty acids. Look for a peroxide-value specification, an added tocopherol, an opaque softgel and a far-off expiry, and refrigerate after opening. Hexane-extracted oil is cheaper and the residual-solvent specification is the thing to ask about.
Dose across whole cycles, not across weeks. The mastalgia trial ran six months Blommers 2002, and cyclical breast pain is by definition a phenomenon of the cycle. Three complete cycles is the minimum unit of observation, and a course started mid-cycle and abandoned six weeks later has measured your patience.
Topical is a different product with different evidence. Evening primrose oil is also applied to skin, where linoleic acid can contribute to the barrier's acylceramides directly rather than through a desaturase. That is a separate mechanism and a separate literature, and the null oral trials Bamford 2013 say nothing about it.
What would have to be true, and how you would know it was not
1. Score cycles, and pre-commit to the number. What to watch: days with breast pain per cycle, counted on a calendar rather than remembered. How long before it means anything: three complete cycles minimum, six months to match the trial Blommers 2002. What will fool you: the control oil in that trial cut painful days by 13.8% Blommers 2002, so a 10 to 15% improvement is the expected result of taking any capsule at all, and it will feel like a result.
2. The prediction that cuts against the product, and it is the sharpest one on this page. Predict that evening primrose oil does not beat an inert oil. That is what happened at six months in a four-arm randomized trial, 12.3% against 13.8%, P = .73 Blommers 2002. If you want a real personal test, run olive oil capsules for three cycles and evening primrose for three cycles without knowing which is which — and predict you cannot tell them apart.
3. Predict nothing on eczema, and watch the emollient instead. The pooled estimate is a mean difference of −2.22 with an interval spanning zero Bamford 2013. Score one patch photographed in fixed light for twelve weeks if you want, but hold the emollient constant, because in this condition the moisturizer is the intervention with the evidence and the capsule is the one without it.
4. Predict your hormones do not move, and understand why that is not a failure. Serum prolactin and estradiol are typically normal in cyclical mastalgia and the proposed mechanism is tissue responsiveness rather than hormone concentration. So predict no change on a hormone panel, and note that a normal panel neither supports nor refutes the product — which is exactly why this page does not recommend one.
5. If you insist on testing GLA rather than testing this bottle, test it at the dose that once worked. That means about 2.8 g of GLA a day Zurier 1996, which is thirty evening primrose capsules or a dozen borage ones. Predict that at label doses you are not testing the hypothesis at all, and that a null result at 500 mg tells you about the dose rather than about the molecule.
What nobody has tested yet
Nobody has genotyped a GLA trial. The hypothesis behind this entire product is impaired delta-6-desaturase capacity, and FADS1 and FADS2 polymorphisms are a large, cheap, measurable source of exactly that variation. A trial enrolling only slow-converter genotypes has never been run, which means every null result Blommers 2002 Bamford 2013 averaged the people the theory predicts should respond with the people it predicts should not.
Nobody has taken the effective GLA dose into these indications. 2.8 g a day worked in rheumatoid arthritis Zurier 1996; mastalgia and eczema were tested at a fraction of it Blommers 2002 Bamford 2013. The dose-matched trial has never been done, and the withdrawal of the UK licenses removed the commercial reason to do it.
Nobody has measured the tissue. The mechanism claims a change in breast tissue membrane composition and sensitivity. Breast tissue is biopsied routinely for other reasons, red-cell membrane fatty acid panels are cheap, and no mastalgia trial has reported either alongside its clinical endpoint.
And nobody has explained the control oils. An inert oil cut painful days by 13.8% over six months Blommers 2002. Whether that is placebo response, regression to the mean, or an actual effect of several grams a day of a control fat is unknown, and it is the most interesting unanswered question in the whole mastalgia literature — because it sets the bar every future product has to clear.
Evening Primrose Oil — its own safety story, not its category's
The seizure warning on this product has been examined and it does not survive. The caution traces to old case reports in patients taking phenothiazine antipsychotics and became a standard formulary entry. A review of the evidence concluded that the association of evening primrose oil with seizures is spurious, that linoleic acid and gamma-linolenic acid are safe in epilepsy, and that formularies should now remove seizures and epilepsy as a side effect of evening primrose oil Puri 2007. That is a direct contradiction of a warning still printed widely, including on this site's own card, and it is stated here because a person with epilepsy deserves the primary source rather than the inherited caution. It remains a conversation to have with a neurologist, on the strength of that paper, rather than a reason for a blanket refusal.
Bleeding risk is real, pharmacodynamic, and invisible to blood tests. GLA-derived eicosanoids reduce platelet aggregation. On warfarin, apixaban, rivaroxaban, clopidogrel or aspirin at any dose the effect adds rather than showing up as a changed drug level: the observable is bruising, nosebleeds or a raised INR. Stop it at least two weeks before surgery or a dental extraction, and tell the surgeon, who will ask about prescriptions and not about supplements.
Pregnancy is the one place the mechanism argues for real caution. Prostaglandin E1 ripens the cervix, which is why this oil has both a folk use near term and a caution earlier. That is a pharmacological reason rather than an absence of data, and it makes this a supervised decision in late pregnancy and one to avoid earlier without a specific reason.
Gastrointestinal upset, nausea and headache are the common reports, and they scale with the number of capsules — which matters because any dose approaching the tested GLA range Zurier 1996 is a great many capsules of this particular oil.
And the thing worth saying last: a license withdrawal is a safety feature. When the regulator reviewed this product it concluded that the evidence did not support the claims, and the product remained available as a supplement. That is the whole regulatory asymmetry in one example, and the correct response is to hold this oil to the trials Blommers 2002 Bamford 2013 rather than to the fact that it is still on the shelf.
Sources read for this page
- Blommers J, et al. Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. American Journal of Obstetrics and Gynecology, 2002 · PMID 12439536
- Bamford JT, et al. Oral evening primrose oil and borage oil for eczema. Cochrane Database of Systematic Reviews, 2013 · PMID 23633319
- Puri BK. The safety of evening primrose oil in epilepsy. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2007 · PMID 17764919
- Zurier RB, et al. gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis and Rheumatism, 1996 · PMID 8912502
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Cyclical breast pain scored across whole menstrual cycles, or eczema scored on one patch photographed in fixed light. Those are the two indications it was actually prescribed for, and they carry the trial history — the good and the bad of it.
- How long before it means anything: Three full cycles, or twelve weeks for skin. GLA has to be converted and incorporated before prostaglandin balance changes, so anything shorter is testing your adherence rather than the oil.
- What will fool you: The strongest single data point on this product is a withdrawal: the UK license for eczema and mastalgia was pulled in 2002 because the accumulated evidence did not support efficacy. Cyclical pain also varies cycle to cycle and eczema remits and relapses by itself, so any run shorter than three cycles is measuring the natural rhythm of the complaint.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Evening Primrose Oil — safety & side effects
- GI upset, nausea and headache.
- Lowers the seizure threshold — avoid with epilepsy, and specifically with phenothiazine antipsychotics, where seizures have been reported.
- Antiplatelet activity. Additive bleeding risk with anticoagulants and antiplatelets — warfarin, apixaban, rivaroxaban, clopidogrel, and aspirin at any dose. The interaction is pharmacodynamic rather than metabolic, so it does not show up as a changed drug level; it shows up as bruising, nosebleeds or a raised INR. Stop at least two weeks before any surgery or dental extraction. Surgeons ask about prescription blood thinners and rarely about supplements, so this one is on you to volunteer.
- Avoid in pregnancy other than under supervision near term.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Evening Primrose Oil in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Evening Primrose Oil
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Ferritin | Below 50 and hair and skin repair suffer, whatever else you take |
| Vitamin D (25-Hydroxy) | Skin, bone and connective tissue all depend on it |
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease shows in hair, skin and nails first |
| Zinc, Plasma | Deficiency causes poor wound healing and hair shedding |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Evening Primrose Oil — frequently asked questions
What is Evening Primrose Oil?
A source of GLA (gamma-linolenic acid), an anti-inflammatory omega-6 used for skin (eczema), hormonal/PMS and breast-pain support.
What is the suggested dose of Evening Primrose Oil?
500–1,300 mg (standardized GLA) daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Evening Primrose Oil dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Evening Primrose Oil?
Coach Cam sources Evening Primrose Oil from vetted, top-rated brands on iHerb — use the buy link on this page.
Evening Primrose Oil inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Evening Primrose Oil is used for
Evening Primrose Oil appears under 2 goals in the goal router.
Related Skin & Structural supplements
Where this goes next
Evening Primrose Oil is the inflammatory-skin arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.